Fate Therapeutics gives Q3 2026 update on lupus CAR T program and FT839 trial sitesNov 10Regulatory decisionAutolus Therapeutics plcFate TherapeuticsUpdated
Genmab's Phase 3 China DLBCL trial of epcoritamab posts results, listed active not recruitingNov 10Trial updateAbbVieepcoritamab-bysp
Genmab's EPCORE DLBCL-1 Phase 3 trial posts results after primary completion in October 2026Nov 3Trial updateAbbVieepcoritamab-bysp
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Loxo posts Phase 3 pirtobrutinib results; five more Lilly-linked trials updateSep 25Weekly roundup, 6 itemsabemaciclibbrenipatide
Fate Therapeutics doses first lupus nephritis patient in Phase 2 FT819 trial, clears FT839 INDAug 13Quarterly updateFate TherapeuticsFT819
BeOne Medicines reports Q2 2026 results, raises full-year revenue guidanceAug 5Quarterly updateBeiGenesonrotoclax